Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29153537 | 1.00 | MEN1 (0.34) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL30977209 | 1.00 | MEN1 (0.34) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL29153539 | 1.00 | MEN1 (0.34) | MEN1KMT2ACA1CA2CA9 | |
| Potassium Ion SCHEMBL29084677 | 0.93 | MEN1 (0.36) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL26276091 | 0.85 | CA1 (0.34) | CA1CA2CA9MAOA | |
| SCHEMBL7658801 | 0.82 | KMT2A (0.39) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL27218964 | 0.81 | MEN1 (0.34) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL24728326 | 0.79 | CA1 (0.35) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL26623056 | 0.78 | CA1 (0.33) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL26623059 | 0.78 | CA1 (0.33) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4601701-A1 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-120058723-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119997983-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119948031-A | Ligand-drug conjugates of isatecan analogs and medical uses thereof | 广州百济神州生物制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119899238-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-117567478-B | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4514396-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-119212732-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024078586-A9 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023208216-A9 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024078586-A1 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-4349372-A1 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024067811-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE, LTD. (KY) | 2024-04-04 | — | — | WO | disclosed |
| CN-117567478-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117500527-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023208216-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | TOP1, TOP2A, TOP2B | MEN1 2546/4885KMT2A 980/4885CA1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.